文献速递药物相互作用药物不良反应与药物警戒治疗药物监测与药物基因组学

药物-基因相互作用及药物基因组学在辛伐他汀相关肺毒性中的作用

Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity.
PubMed 文献 · Drug Saf · 2021-10-04

本研究为回顾性观察性研究,纳入34例辛伐他汀相关肺毒性(NSIP或IPF)病例,评估合并用药特征及CYP、SLCO1B1基因变异与药物-基因相互作用。结果显示70.5%(n=24)的病例可由CYP3A4底物/抑制剂或≥3种致酸中毒药物解释,遗传变异仅解释20.6%(n=7);停用辛伐他汀或换用水溶性他汀后所有NSIP病例改善或稳定,而换用脂溶性阿托伐他汀者均进展。结论认为该肺毒性为多因素所致,需继续他汀治疗者应考虑换用水溶性他汀。

要点

  • 辛伐他汀相关肺毒性多因素,合并CYP3A4底物/抑制剂或≥3种致酸中毒药物可解释70.5%病例。
  • CYP3A4、CYP2C9、OATP1B1表型在病例与对照间无显著差异,遗传变异仅解释20.6%。
  • 停用辛伐他汀或换用水溶性他汀后NSIP病例均改善或稳定,换用脂溶性阿托伐他汀者均进展。

核心结论

  • 辛伐他汀相关肺毒性为多因素所致,药物-基因相互作用及合并用药特征较遗传变异解释更多病例。
  • 对需继续他汀治疗的患者,应考虑换用水溶性他汀而非脂溶性阿托伐他汀。

研究设计与样本

  • 回顾性观察性研究,纳入34例辛伐他汀相关肺毒性(NSIP或IPF)病例。
  • 评估合并用药特征、CYP及SLCO1B1基因变异和药物-基因相互作用,并在停药或换药6个月后评估结局。
  • 临床试验注册号NCT00267800,2005年注册。

主要发现

  • 70.5%(n=24)病例的辛伐他汀相关毒性可由CYP3A4底物/抑制剂或≥3种致酸中毒药物解释。
  • 病例与对照在CYP3A4、CYP2C9或OATP1B1表型上无显著差异,遗传变异仅解释20.6%(n=7)病例。
  • 停用辛伐他汀未换药或换用水溶性他汀后,所有NSIP病例改善或稳定;换用脂溶性阿托伐他汀者均进展。

关键数值与推荐

  • 合并用药涉及CYP3A4底物和/或抑制剂,或≥3种致酸中毒药物,可解释70.5%(n=24)病例。
  • 遗传变异解释20.6%(n=7)病例。
  • CYP3A4、CYP2C9、OATP1B1表型在病例与对照间无显著差异。

临床怎么用

  • 评估辛伐他汀相关肺毒性时需审查合并用药,尤其CYP3A4底物/抑制剂及致酸中毒药物。
  • 需继续他汀治疗的患者,优先换用水溶性他汀,避免换用脂溶性阿托伐他汀。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Simvastatin has previously been associated with drug-induced interstitial lung disease. In this retrospective observational study, cases with non-specific interstitial pneumonia (NSIP) or idiopathic pulmonary fibrosis (IPF) with simvastatin-associated pulmonary toxicity (n = 34) were evaluated. OBJECTIVE: To identify whether variations in genes encoding cytochrome P450 (CYP) enzymes or in the SLCO1B1 gene (Solute Carrier Organic anion transporting polypeptide 1B1 gene, encoding the organic anion transporting polypeptide 1B1 [OATP1B1] drug transporter enzyme), and/or characteristics of concomitantly used drugs, predispose patients to simvastatin-associated pulmonary toxicity. METHODS: Characteristics of concomitantly used drugs and/or variations in the CYP or SLCO1B1 genes and drug-gene interactions were assessed. The outcome after withdrawal of simvastatin and/or switch to another statin was assessed after 6 months. RESULTS: Multiple drug use involving either substrates and/or inhibitors of CYP3A4 and/or three or more drugs with the potential to cause acidosis explained the simvastatin-associated toxicity in 70.5% (n = 24) of cases. Cases did not differ significantly from controls regarding CYP3A4, CYP2C9, or OATP1B1 phenotypes, and genetic variation explained only 20.6% (n = 7) of cases. Withdrawal of simvastatin without switching to another statin or with a switch to a hydrophilic statin led to improvement or stabilization in all NSIP cases, whereas all cases who were switched to the lipophilic atorvastatin progressed. CONCLUSION: Simvastatin-associated pulmonary toxicity is multifactorial. For patients with this drug-induced pulmonary toxicity who need to continue taking a statin, switching to a hydrophilic statin should be considered. CLINICALTRIALS. GOV IDENTIFIER: NCT00267800, registered in 2005.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Jessurun NT, Drent M, Wijnen PA, et al. Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Saf. 2021. PMID: 34606062. doi:10.1007/s40264-021-01105-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。